Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension.

[1]  R. Benza,et al.  Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. , 2019, Chest.

[2]  D. Sánchez-Quintana,et al.  Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[3]  J. Lumens,et al.  Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update , 2019, European Respiratory Journal.

[4]  Z. Jing,et al.  Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[5]  S. Söderberg,et al.  A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.

[6]  R. Benza,et al.  Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  F. Fedele,et al.  Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  M. Humbert,et al.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[9]  S. Rosenkranz,et al.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[10]  N. Westerhof,et al.  Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[11]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[12]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[13]  N. Westerhof,et al.  Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. , 2015, Chest.

[14]  P. Hassoun,et al.  Noninvasive Imaging in the Assessment of the Cardiopulmonary Vascular Unit , 2015, Circulation.

[15]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[16]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[17]  M. Humbert,et al.  Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study , 2014, European Respiratory Journal.

[18]  J. Marcus,et al.  Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy: The EURO-MR Study , 2014, Circulation. Cardiovascular imaging.

[19]  A. Manes,et al.  Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.

[20]  J. Bronzwaer,et al.  Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension , 2006, Heart.

[21]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[22]  M. Humbert,et al.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.

[23]  D. Dresdale,et al.  Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. , 1954, Bulletin of the New York Academy of Medicine.